The Challenge
Developing gene therapies for rare diseases is a long, slow process, often stalled by the high costs for drug development/manufacturing and low commercial interest, or lack of expertise navigating late-stage preclinical development and the regulatory process. Taking most new treatments from discovery through clinical trials can take a decade and cost tens of millions of dollars. Ultimately, viable treatments are left “on the shelf” and not produced for patients because the return on investment is measured in dollars instead of human impact.

Odylia’s Solution
Odylia Therapeutics works to lower costs, focus strategic research, reduce development time, and continuously drive programs toward clinical trials and regulatory approvals. Our strategic collaborations with patient groups, research labs, and vendors facilitate our work to ensure treatments are safe, effective, and reach patients without inflated costs. To keep a treatment moving toward clinical trials, we identify potential industry partners who would invest in the treatment, but we also seek philanthropic support to ensure the program continues even if there is ultimately no commercial partner.

How You Can Help
One of the longest and most expensive stages of getting a treatment to patients is the manufacturing process. It is at this pivotal point in drug development that viable treatments are stalled. Currently, a substantial investment of $10 million has already been made in three programs managed by Odylia. Each treatment is for a rare disease that causes vision loss.

Life-altering treatments with proof of concept may never reach patients without financial support. With an initial objective of raising $2 million and a long-term goal of raising $8 million for our Manufacturing Fund, we can ensure capital is available for manufacturing and to keep treatments moving into clinical trials.

“What good does it do to create life-altering treatments and never bring them to patients?”

“IT is imperative that we fund manufacturing now so that no patients go blind while viable treatments wait in the lab.”